Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study

作者：Jin‐Ji Yang, Jianying Zhou, Si‐Yang Maggie Liu, Mingjun Li, Zhiye Zhang, Ying Cheng, Yun Fan, Hongming Pan, Baoqing Wang, Gongyan Chen, Ke Wang, Liyan Jiang, Yanping Hu, Jianhua Shi, Xiaorong Dong, Cuimin Ding, Yunpeng Liu, Zhe Liu, Wangjun Liao, Wei Li, Jun Wang, Shanyong Yi, Qiong Zhao, Aimin Zang, Yuan Chen, Jiuwei Cui, Pengfei Luo, Xionghu Shen, Meili Sun, Changli Wang, Yi‐Long Wu, Yi-Long Wu, Yi-Long Wu, Yi-Long Wu, Jin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, Mingjun Li, Zhiye Zhang, Ying Cheng, Yun Fan, Hongming Pan, Baoqing Wang, Gongyan Chen, Ke Wang, Liyan Jiang, Yanping Hu, Jianhua Shi, Xiaorong Dong, Cuimin Ding, Yunpeng Liu, Zhe Liu, Wangjun Liao, Wei Li, Jun Wang, Shanyong Yi, Qiong Zhao, Aimin Zang, Yuan Chen, Jiuwei Cui, Pengfei Luo, Xionghu Shen, Meili Sun, Changli Wang, Yongchun Zhou, Zhuli Wu, Xingli Wang, Juan Sun, Jiayan Guo, Yang Zheng, Xiao Xiang, Ai-min Hui · 发表于：The Lancet Respiratory Medicine · 年份：2024 · DOI：10.1016/s2213-2600(24)00171-1 · 被引用次数：9 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Research Studies、Cancer Immunotherapy and Biomarkers